Biotimize Announces the Opening of a Fundraising Round to Build the First Biological CDMO in Brazil
PIRACICABA, Brazil, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Biotimize, a functional growth-stage biotechnology as a service (BaaS) company with a...
Day: September 5, 2022
Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022
SAN CARLOS, Calif., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative...
Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck
-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05,...
Why Delta 8 Carts By Exhale Are This Year’s Best Pick
GLENDALE, Calif., Sept. 05, 2022 (GLOBE NEWSWIRE) -- New users often do not know the difference between Delta 8 and...
Alvotech Reports Update on Initial AVT02 Biologics License Application
REYKJAVIK, Iceland, Sept. 05, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and...
Alvotech Reports Update on Initial AVT02 Biologics License Application
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced...
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children...
Orion recalls Devisol Salmiakki dietary supplement from consumers
Devisol_Salmiakki_20mikrog_200tabl Devisol_Salmiakki_20mikrog_200tabl Devisol_Salmiakki_20mikrog_230tabl Devisol_Salmiakki_20mikrog_230tablORION CORPORATION PRESS RELEASE 5 SEPTEMBER 2022 AT 8.00 EEST Orion recalls Devisol Salmiakki dietary supplement from consumers...
Press Release: Evolution of the Board of Directors
Evolution of the Board of Directors Paris, September 5, 2022. The Board of Directors of Sanofi met on September 2,...
Bone Therapeutics to host Extraordinary General Meeting on 05 October 2022
REGULATED INFORMATION As a result of a technical error in the publication dated August 26, 2022, the Board of Directors...
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. HansenINDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) --...
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not...